An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing.
Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by…
Source: www.labiotech.eu – Read more